{ "meta": { "data_length": 1, "message": "Statement id stmt:ema:gavreto:0:0 retrieved successfully", "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Aema%3Agavreto%3A0%3A0", "status": "success", "status_code": 200, "timestamp_elapsed": 0.002088, "timestamp_received": "2026-10-17T00:00:55.170910+00:00Z", "timestamp_returned": "2026-10-17T00:00:55.172998+00:00Z", "trace_id": "18b91d0c-f835-4c4c-9306-4bbda012a0db" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:ema:gavreto:0:0", "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pralsetinib as a monotherapy treatment for adult patients with RET fusion-positive advanced non-small cell lung cancer (NSCLC) who have not previously been treated with a RET inhibitor.", "contributions": [ { "id": "ctrb:vanallenlab:2025-08-29:4", "type": "Contribution", "description": "On 2024-10-24, the European Commission withdrew the market authorization for Gavreto (pralsetinib) in the European Union at the request of the marketing authorization holder, Blueprint Medicines (Netherlands) B.V., due to their decision to permanently discontinue the marketing of the product for commercial reasons.", "date": "2025-08-29", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:vanallenlab:2024-10-20:0", "type": "Contribution", "description": "Adding EMA approvals for use to database", "date": "2024-10-20", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:ema:2021-11-18:0", "type": "Contribution", "description": "Indication received approval from the European Commission.", "date": "2021-11-18", "contributor": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." } } ], "reportedIn": [ { "id": "doc:ema:gavreto", "type": "Document", "documentType": "Regulatory approval", "name": "Gavreto (pralsetinib) [product information]. EMA.", "title": null, "aliases": [], "description": "Roche Registration GmbH. Gavreto (pralsetinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/gavreto-epar-product-information_en.pdf. Revised January 2025. Accessed August 29, 2025.", "urls": [ "https://www.ema.europa.eu/en/documents/product-information/gavreto-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/gavreto" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." }, "description": "The organization that published this document." }, { "name": "company", "value": "Roche Registration GmbH.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Gavreto", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "pralsetinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2021-12-09", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-01-17", "description": "The publication date for the document." }, { "name": "status", "value": "Deprecated", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:364", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:ncit:C2926", "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2025_10_03", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Non-Small+Cell+Lung+Cancer+%28NSCLC%29" ] } } ], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:ncit:C2926", "code": "C2926", "name": "Lung Non-Small Cell Carcinoma", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2926" ] } }, "objectTherapeutic": { "id": "tx:ncit:C132295", "conceptType": "Therapy", "name": "Pralsetinib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:2394936", "code": "2394936", "name": "pralsetinib", "system": "RxNorm", "systemVersion": "20250602", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2394936" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:37002765", "code": "37002765", "name": "pralsetinib", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/37002765" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "RET inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C132295", "code": "C132295", "name": "Pralsetinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132295" ] } }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:18", "present": true, "subject": { "id": "bmkr:18", "type": "CategoricalVariant", "name": "v::RET", "constraints": [ { "type": "AdjacencyConstraint", "orderKnown": false, "adjoinedElements": [ { "id": "gene:hgnc:9967", "conceptType": "Gene", "name": "RET", "primaryCoding": { "id": "coding:hgnc:9967", "code": "HGNC:9967", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9967" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000165731", "code": "ENSG00000165731", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000165731" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:5979", "code": "5979", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/5979" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_020975.6", "code": "NM_020975.6", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.6" ] } } ] }, { "type": "UnspecifiedElement" } ] } ], "extensions": [ { "name": "biomarker_type", "value": "Gene fusion" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Deprecated", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:ema:gavreto:0", "type": "Indication", "description": "Gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.", "contributions": [ { "id": "ctrb:vanallenlab:2025-08-29:4", "type": "Contribution", "description": "On 2024-10-24, the European Commission withdrew the market authorization for Gavreto (pralsetinib) in the European Union at the request of the marketing authorization holder, Blueprint Medicines (Netherlands) B.V., due to their decision to permanently discontinue the marketing of the product for commercial reasons.", "date": "2025-08-29", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:vanallenlab:2024-10-20:0", "type": "Contribution", "description": "Adding EMA approvals for use to database", "date": "2024-10-20", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:ema:2021-11-18:0", "type": "Contribution", "description": "Indication received approval from the European Commission.", "date": "2021-11-18", "contributor": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." } } ], "reportedIn": [ { "id": "doc:ema:gavreto", "type": "Document", "documentType": "Regulatory approval", "name": "Gavreto (pralsetinib) [product information]. EMA.", "title": null, "aliases": [], "description": "Roche Registration GmbH. Gavreto (pralsetinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/gavreto-epar-product-information_en.pdf. Revised January 2025. Accessed August 29, 2025.", "urls": [ "https://www.ema.europa.eu/en/documents/product-information/gavreto-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/gavreto" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." }, "description": "The organization that published this document." }, { "name": "company", "value": "Roche Registration GmbH.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Gavreto", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "pralsetinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2021-12-09", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-01-17", "description": "The publication date for the document." }, { "name": "status", "value": "Deprecated", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Withdrawn", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }